Sylvant Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Sylvant General Information

Description

A monoclonal antibody medicine used to treat people with Multicentric Castleman's Disease (MCD). The drug blocks the action of interleukin-6 (IL-6), a multifunctional cytokine detected at elevated levels in patients with Idiopathic MCD (iMCD), an inflammatory lymphoproliferative disorder that causes the abnormal overgrowth of immune cells and shares many symptomatic.

Contact Information

Website
www.sylvant.com
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • PO Box 200
  • Titusville, NJ
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Corporate Office
  • PO Box 200
  • Titusville, NJ
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sylvant Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sylvant‘s full profile, request access.

Request a free trial

Sylvant Patents

Sylvant Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2015077966-A1 Crystal form of nucleoside inhibitor of hcv Inactive 28-Nov-2013
WO-2015059212-A1 Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b Inactive 23-Oct-2013
WO-2015014836-A1 Substituted pyridine-piperazinyl analogues as rsv antiviral compounds Inactive 30-Jul-2013
WO-2015014815-A1 Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections Inactive 30-Jul-2013
WO-2015011281-A1 Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b Inactive 25-Jul-2013 C07D207/34
To view Sylvant’s complete patent history, request access »

Sylvant Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sylvant‘s full profile, request access.

Request a free trial

Sylvant FAQs

  • Where is Sylvant headquartered?

    Sylvant is headquartered in Titusville, NJ.

  • What industry is Sylvant in?

    Sylvant’s primary industry is Buildings and Property.

  • Is Sylvant a private or public company?

    Sylvant is a Private company.

  • What is the current valuation of Sylvant?

    The current valuation of Sylvant is .

  • What is Sylvant’s current revenue?

    The current revenue for Sylvant is .

  • Who are Sylvant’s investors?

    Johnson&Johnson Innovative Medicine has invested in Sylvant.

  • When was Sylvant acquired?

    Sylvant was acquired on 01-Jul-2018.

  • Who acquired Sylvant?

    Sylvant was acquired by EUSA Pharma (UK).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process